Inmed to supply rare cannabinoids to radicle science's “radicle energy study” to assess the health effects of thcv

Vancouver, british columbia and south san francisco, calif., may 05, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce that its subsidiary, baymedica, will be providing rare cannabinoids for use in radicle science, inc.'s radicle energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin (“thcv”) on energy, focus/attention, appetite and weight/bmi. baymedia will be supplying its highly pure d-9 dominant thcv, formulated into a proprietary lozenge manufactured by trokie.
INM Ratings Summary
INM Quant Ranking